Our study found that, despite multiple guidelines recommending against its routine use in men aged 70 years and older, PSA tests for prostate cancer screening were highly prevalent among Medicare Advantage beneficiaries and associated with substantial amounts of potentially avoidable care. Here, KLK3 is linked to prostate cancer.